| Literature DB >> 31373655 |
Christopher M Warren1, Avneet S Chadha1, Scott H Sicherer2, Jialing Jiang1, Ruchi S Gupta1.
Abstract
Importance: Sesame allergy is of growing concern in the United States. The US Food and Drug Administration recently issued a request for epidemiological data on the prevalence and severity of sesame allergies in the United States to inform possible regulatory action requiring sesame to be labeled as an allergen on packaged foods. Objective: To provide current estimates of the prevalence, severity, distribution, and clinical characteristics of sesame allergy in the United States. Design, Setting, and Participants: This cross-sectional study assessed findings of web- and telephone-based food allergy questionnaires. Study participants were first recruited from NORC (National Opinion Research Center) at the University of Chicago's probability-based AmeriSpeak panel, and additional participants were recruited through Survey Sampling International. Surveys were administered to a nationally representative sample of 51 819 US households from October 1, 2015, through September 31, 2016. Responses for 40 453 adults and 38 408 children were included in the analysis. Data were analyzed from January 1, 2017, through May 1, 2019. Exposures: Demographic and allergic characteristics of participants. Main Outcomes and Measures: Self-reported sesame allergy was the main outcome and was considered convincing if reported symptoms to sesame-allergic reactions were consistent with an IgE-mediated reaction. Diagnostic history of specific allergens and use of food allergy-related health care services were also primary outcomes.Entities:
Mesh:
Year: 2019 PMID: 31373655 PMCID: PMC6681546 DOI: 10.1001/jamanetworkopen.2019.9144
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Prevalence of Sesame Allergies by Age and Frequency
| Age Group | Sesame Allergy Characteristic | |||
|---|---|---|---|---|
| Reported | History of Convincing Symptoms or Physician Diagnosis | History of Convincing Symptoms | Physician Diagnosis | |
| No. of children | 206 | 158 | 102 | 56 |
| No. of adults | 273 | 204 | 149 | 61 |
| All | 0.49 (0.40-0.58) | 0.34 (0.29-0.41) | 0.23 (0.19-0.28) | 0.10 (0.08-0.12) |
| All children (<18 y) | 0.53 (0.39-0.72) | 0.41 (0.28-0.60) | 0.21 (0.16-0.28) | 0.12 (0.08-0.17) |
| 0-2 y | 0.58 (0.34-0.99) | 0.38 (0.22-0.68) | 0.26 (0.12-0.54) | 0.12 (0.04-0.39) |
| 3-5 y | 0.45 (0.29-0.70) | 0.34 (0.21-0.56) | 0.23 (0.13-0.41) | 0.16 (0.08-0.32) |
| 6-10 y | 0.61 (0.36-1.02) | 0.53 (0.29-0.95) | 0.27 (0.16-0.44) | 0.15 (0.08-0.30) |
| 11-13 y | 0.74 (0.28-1.95) | 0.61 (0.19-2.0) | 0.14 (0.07-0.27) | 0.09 (0.04-0.21) |
| 14-17 y | 0.31 (0.17-0.55) | 0.20 (0.13-0.32) | 0.15 (0.09-0.26) | 0.06 (0.03-0.11) |
| All adults (≥18 y) | 0.44 (0.38-0.52) | 0.32 (0.27-0.39) | 0.24 (0.19-0.29) | 0.09 (0.07-0.12) |
| 18-29 y | 0.59 (0.46-0.76) | 0.47 (0.36-0.61) | 0.33 (0.24-0.44) | 0.17 (0.11-0.26) |
| 30-39 y | 0.62 (0.49-0.81) | 0.44 (0.32-.060) | 0.31 (0.21-0.45) | 0.12 (0.07-0.21) |
| 40-49 y | 0.53 (0.36-0.77) | 0.31 (0.20-0.46) | 0.23 (0.15-0.37) | 0.08 (0.04-0.16) |
| 50-59 y | 0.42 (0.26-0.67) | 0.37 (0.22-0.62) | 0.28 (0.15-.053) | 0.10 (0.05-0.21) |
| ≥60 y | 0.17 (0.10-0.29) | 0.12 (0.07-0.22) | 0.09 (0.04-0.17) | 0.003 (0.00-0.02) |
| All | 4.18 (3.44-5.07) | 2.91 (2.44-3.47) | 2.29 (1.92-2.74) | 0.95 (0.75-1.19) |
| All children (<18 y) | 5.4 (3.9-7.5) | 4.3 (2.9-6.4) | 2.7 (2.1-3.6) | 1.5 (1.0-2.2) |
| 0-2 y | 6.31 (3.66-10.66) | 4.9 (2.6-8.9) | 3.55 (1.68-7.38) | 1.67 (0.51-5.29) |
| 3-5 y | 4.02 (2.41-6.62) | 3.7 (2.2-6.3) | 2.74 (1.50-4.97) | 1.86 (0.90-3.83) |
| 6-10 y | 5.14 (3.50-7.49) | 4.3 (2.8-6.6) | 3.33 (2.00-5.49) | 1.94 (0.99-3.75) |
| 11-13 y | 8.46 (2.93-22.08) | 6.7 (1.7-22.6) | 1.83 (0.95-3.52) | 1.24 (0.55-2.76) |
| 14-17 y | 4.09 (2.23-7.41) | 2.7 (1.7-4.2) | 2.11 (1.20-3.67) | 0.82 (0.42-1.58) |
| All adults (≥18 y) | 3.3 (2.8-3.9) | 2.6 (2.2-3.2) | 2.20 (1.8-2.7) | 0.82 (0.62-1.1) |
| 18-29 y | 4.28 (3.28-5.56) | 3.4 (2.6-4.5) | 2.90 (2.14-3.92) | 1.47 (0.93-2.31) |
| 30-39 y | 4.22 (3.21-5.53) | 3.0 (2.1-4.1) | 2.44 (1.66-3.56) | 0.97 (0.57-1.67) |
| 40-49 y | 3.64 (2.53-5.22) | 2.8 (1.9-4.2) | 2.33 (1.49-3.62) | 0.81 (0.40-1.63) |
| 50-59 y | 3.32 (2.04-5.37) | 2.9 (1.7-5.0) | 2.38 (1.27-4.42) | 0.84 (0.41-1.74) |
| ≥60 y | 1.25 (0.70-2.20) | 1.1 (0.6-2.0) | 1.00 (0.51-1.93) | 0.03 (0.004-0.21) |
Expressed as frequency (95% CI) in percentages.
Demographic Distribution of Convincing Sesame Allergy vs No Allergy and Top 8 Allergies
| Variable | Population-Weighted Frequency, % (95% CI) | Current Convincing Allergy to Other Top 8, Population-Weighted Frequency (95% CI), % | |||
|---|---|---|---|---|---|
| All Respondents | Current Convincing Sesame Allergy | ||||
| Race/ethnicity | |||||
| Asian non-Hispanic | 3.7 (3.5-4.0) | 3.0 (1.3-7.0) | .63 | 4.3 (3.6-5.0) | .43 |
| Black non-Hispanic | 12.0 (11.6-12.5) | 13.1 (8.5-19.4) | .70 | 13.6 (12.3-15.1) | .84 |
| White non-Hispanic | 62.2 (61.4-62.9) | 56.2 (47.2-64.8) | .17 | 56.8 (54.8-58.7) | .90 |
| Hispanic | 17.4 (16.7-18.1) | 24.7 (17.6-33.6) | .04 | 19.4 (17.8-21.2) | .17 |
| Multiple or other | 4.7 (4.4-4.9) | 3.0 (1.2-7.4) | .35 | 5.9 (5.0-7.0) | .15 |
| Sex | |||||
| Male | 48.9 (48.4-49.5) | 44.8 (36.7-53.1) | .33 | 38.9 (37.1-40.7) | .17 |
| Female | 51.1 (50.5-51.6) | 55.2 (46.9-63.3) | 61.1 (59.3-62.9) | ||
| Age, y | |||||
| 0-2 | 3.6 (.3.4-3.8) | 4.0 (1.9-8.0) | .01 | 3.0 (2.4-3.8) | .39 |
| 3-5 | 3.6 (3.5-3.8) | 3.6 (2.0-6.5) | 3.2 (2.7-3.8) | ||
| 6-10 | 6.2 (6.0-6.5) | 6.2 (4.3-11.8) | 5.7 (5.1-6.4) | ||
| 11-13 | 3.7 (3.5-3.9) | 2.2 (1.2-4.3) | 3.3 (2.8-3.9) | ||
| 14-17 | 5.2 (5.0-5.5) | 3.4 (1.9-5.9) | 4.0 (3.5-4.6) | ||
| 18-29 | 16.7 (16.2-17.2) | 23.7 (17.6-31.0) | 19.5 (18.0-21.2) | ||
| 30-39 | 13.2 (12.8-13.5) | 17.7 (12.3-24.9) | 17.4 (16.0-18.9) | ||
| 40-49 | 13.0 (12.6-13.4) | 13.2 (8.5-19.8) | 12.7 (11.5-13.9) | ||
| 50-59 | 14.0 (13.6-14.4) | 17.2 (9.7-28.6) | 15.5 (14.2-16.9) | ||
| ≥60 | 20.8 (20.3-21.3) | 7.9 (4.1-14.5) | 15.8 (14.5-17.3) | ||
| Household income, $ | |||||
| <25 000 | 16.5 (16.0-17.0) | 11.9 (7.4-18.5) | .15 | 15.6 (14.2-17.0) | .25 |
| 25 000-49 999 | 22.0 (21.4-22.6) | 21.6 (14.9-30.1) | .91 | 22.1 (20.6-23.6) | .90 |
| 50 000-99 999 | 31.0 (30.3-31.7) | 35.1 (27.8-43.2) | .28 | 34.0 (32.3-35.9) | .79 |
| 100 000-149 999 | 19.5 (18.9-20.2) | 23.1 (15.2-33.5) | .42 | 19.9 (18.2-21.7) | .48 |
| ≥150 000 | 11.0 (10.5-11.6) | 8.4 (5.0-13.7) | .28 | 8.5 (7.4-9.7) | .97 |
| Physician-diagnosed comorbid conditions | |||||
| Asthma | 12.2 (11.8-12.7) | 27.2 (20.5-35.1) | <.001 | 26.3 (24.7-28.0) | .82 |
| Atopic dermatitis or eczema | 6.5 (6.2-6.9) | 13.7 (9.0-20.3) | <.001 | 13.1 (11.9-14.4) | .83 |
| Eosinophilic esophagitis | 0.2 (0.1-0.2) | 3.6 (1.4-8.7) | <.001 | 0.5 (0.4-0.8) | <.001 |
| Food protein–induced enterocolitis | 0.3 (0.2-0.3) | 4.4 (2.4-7.9) | <.001 | 1.8 (1.4-2.2) | .004 |
| Environmental allergies | 19.5 (19.0-20.0) | 24.6 (18.1-32.6) | .13 | 32.9 (31.2-34.7) | .04 |
| Insect sting allergy | 3.5 (3.3-3.7) | 7.0 (3.8-12.6) | .02 | 7.0 (6.2-7.9) | .99 |
| Latex allergy | 2.0 (1.9-2.2) | 8.6 (5.1-14.1) | <.001 | 6.3 (5.4-7.3) | .26 |
| Medication allergy | 11.3 (11.0-11.7) | 18.8 (11.3-29.6) | .048 | 18.5 (17.1-20.0) | .95 |
| Urticaria or chronic hives | 0.8 (0.7-0.9) | 1.7 (0.6-5.0) | .15 | 2.3 (1.9-2.8) | .60 |
| Other chronic condition | 6.4 (6.1-6.7) | 8.1 (4.6-13.8) | .40 | 7.9 (6.9-8.9) | .92 |
| Parental history of atopy | |||||
| Asthma | 14.7 (14.2-15.2) | 41.0 (31.4-51.4) | <.001 | 26.6 (24.8-28.3) | .002 |
| Eczema | 11.1 (10.6-11.5) | 29.9 (22.3-38.7) | <.001 | 19.7 (18.2-21.3) | .007 |
| Allergic rhinitis | 31.6 (30.9-32.4) | 52.5 (42.9-61.9) | .001 | 47.5 (45.4-49.7) | .33 |
| Food allergy | 14.6 (14.1-15.1) | 50.4 (40.3-60.4) | <.001 | 42.2 (40.1-44.3) | .12 |
Sesame Allergy Reaction Symptoms
| Symptom Reported | Population-Weighted Frequency, % (95% CI) | ||
|---|---|---|---|
| Convincing Allergy to Top 8 Allergens (n = 6942) | Convincing Sesame Allergy During Most Severe Reaction to Sesame (n = 251) | Physician-Confirmed, Convincing IgE-Mediated Sesame Allergy Reporting Each Symptom During Most Severe Reaction to Sesame (n = 117) | |
| Skin or oral mucosal tissue | |||
| Hives | 57.9 (56.0-59.8) | 71.6 (63.3-78.7) | 69.5 (58.2-78.8) |
| Itching | 59.3 (57.4-61.2) | 54.9 (46.1-63.5) | 57.9 (46.1-68.9) |
| Rash | 45.0 (43.1-46.8) | 30.3 (23.2-38.5) | 39.1 (28.4-51.0) |
| Swelling | 26.7 (25.1-28.4) | 17.9 (11.7-26.3) | 18.6 (10.9-30.0) |
| Lip or tongue swelling | 32.7 (31.0-34.5) | 26.1 (17.8-36.6) | 28.6 (19.2-40.4) |
| Difficulty swallowing | 35.5 (33.7-37.3) | 20.5 (14.7-28.0) | 27.5 (18.1-39.4) |
| Hoarse voice | 17.4 (16.0-18.8) | 15.5 (9.9-23.4) | 18.6 (10.9-29.9) |
| Itchy mouth | 31.7 (30.0-33.5) | 19.2 (13.8-26.2) | 25.8 (17.3-36.6) |
| Throat tightening | 31.4 (29.7-33.1) | 18.6 (12.6-26.6) | 16.3 (9.5-26.7) |
| Mouth or throat tingling | 21.9 (20.3-23.5) | 9.7 (6.0-15.2) | 13.8 (7.2-24.8) |
| Respiratory tract | |||
| Chest tightening | 22.6 (21.1-24.2) | 14.1 (9.4-20.6) | 15.6 (8.5-26.9) |
| Nasal congestion | 19.5 (18.0-21.1) | 13.6 (8.3-21.5) | 15.8 (9.0-26.2) |
| Repetitive cough | 15.8 (14.4-17.3) | 7.1 (4.1-11.9) | 8.0 (4.1-14.8) |
| Trouble breathing | 29.0 (27.3-30.8) | 22.6 (15.9-31.1) | 23.1 (14.7-34.4) |
| Wheezing | 21.8 (20.3-23.3) | 7.4 (4.4-12.0) | 8.5 (4.1-16.8) |
| Gastrointestinal tract | |||
| Belly pain | 36.8 (34.9-38.8) | 12.8 (8.3-19.3) | 18.3 (10.6-29.8) |
| Cramps | 34.1 (32.2-36.0) | 16.6 (10.7-24.9) | 18.2 (10.7-29.2) |
| Diarrhea | 35.5 (33.6-37.4) | 11.2 (7.2-17.1) | 13.3 (7.4-22.7) |
| Nausea | 35.5 (33.7-37.4) | 18.6 (12.3-27.1) | 17.2 (10.2-27.6) |
| Vomiting | 33.4 (31.6-35.3) | 8.3 (4.8-13.9) | 8.2 (3.8-17.0) |
| Cardiovascular | |||
| Chest pain | 9.7 (8.7-10.9) | 11.5 (7.1-18.0) | 14.6 (7.8-25.6) |
| Rapid heart rate | 16.7 (15.4-18.1) | 15.6 (9.8-23.9) | 13.9 (7.4-24.5) |
| Fainting or dizziness | 16.7 (15.3-18.2) | 13.1 (8.5-19.9) | 14.8 (8.0-25.7) |
| Low blood pressure | 5.3 (4.5-6.2) | 6.8 (2.9-14.8) | 4.2 (1.7-10.1) |
Sesame Allergy Characteristic
| Variable | Population-Weighted Frequency, % (95% CI) | ||
|---|---|---|---|
| Individuals With Convincing Sesame Allergy | Individuals With Physician-Diagnosed, Convincing IgE-Mediated Sesame Allergy | Individuals With Physician-Diagnosed, Sesame Allergy Without Convincing Symptom Report | |
| Severe sesame allergic reaction | |||
| Stringent reaction symptoms occurring within multiple organ systems | 37.2 (29.2-45.9) | 43.1 (32.4-54.5) | 0 |
| Wheeze, fainting or dizziness, and/or low BP only | 23.6 (16.9-32.0) | 25.9 (17.1-37.2) | 0 |
| Physician diagnosed | 41.3 (33.2-49.9) | 100 | 100 |
| Adult-onset (among adults only) | 25.7 (18.1-35.1) | 26.3 (151.0-41.7) | 21.0 (11.7-34.7) |
| Multiple convincing food allergies | 81.6 (71.0-88.9) | 85.7 (74.9-92.3) | 59.6 (32.0-82.2) |
| Current epinephrine prescription | 62.2 (53.4-70.4) | 74.2 (63.2-82.8) | 77.7 (59.3-89.3) |
| Food allergy–related ED visits | |||
| ≥1 Lifetime | 64.6 (55.0-73.1) | 69.0 (56.8-79.1) | 44.2 (24.0-66.5) |
| ≥1 In the past year | 31.8 (24.3-40.5) | 31.4 (22.3-42.1) | 24.6 (12.4-43.0) |
| Comorbid allergy | |||
| Peanut | 46.9 (38.2-55.8) | 51.6 (40.1-63.0) | 37.1 (21.4-56.2) |
| Tree nut | 34.8 (27.2-43.3) | 36.1 (25.8-47.8) | 17.7 (10.5-28.3) |
| Milk | 20.1 (14.8-26.7) | 22.2 (14.3-33.0) | 11.9 (6.5-20.6) |
| Shellfish | 27.5 (20.7-35.6) | 23.5 (14.9-34.9) | 9.2 (4.1-19.6) |
| Egg | 24.9 (18.0-33.4) | 21.1 (13.3-31.9) | 7.1 (3.4-14.3) |
| Fin fish | 21.1 (14.6-29.4) | 13.7 (7.7-23.0) | 6.0 (2.3-15.0) |
| Wheat | 18.9 (13.6-25.6) | 25.1 (16.5-36.3) | 5.6 (1.8-16.0) |
| Soy | 26.6 (20.0-34.3) | 25.9 (17.2-37.0) | 2.3 (1.0-5.3) |
| Sesame allergy diagnosis | |||
| Skin prick or scratch test | 58.3 (47.6-68.3) | 73.3 (62.8-81.7) | 43.1 (28.4-59.2) |
| Blood test | 29.7 (21.5-39.5) | 37.4 (27.4-48.6) | 52.8 (36.4-68.7) |
| OFC | 10.8 (6.5-17.3) | 13.6 (8.2-21.6) | 7.8 (3.4-16.9) |
| Used to treat a sesame-allergic reaction | |||
| EAI | 33.7 (26.3-42.0) | 43.3 (32.3-55.1) | 9.5 (4.6-18.5) |
| Antihistamines | 49.8 (40.9-58.7) | 56.9 (45.3-67.9) | 49.9 (33.3-66.5) |
| Asthma inhaler | 9.0 (5.7-14.1) | 14.3 (8.1-24.1) | 6.0 (2.7-12.8) |
| Corticosteroids | 12.8 (8.3-19.2) | 12.5 (7.0-21.3) | 5.7 (2.1-14.6) |
Abbreviations: BP, blood pressure; EAI, epinephrine autoinjector; ED, emergency department; OFC, oral food challenge.